Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC

Barclays PLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 18.3% during the third quarter, HoldingsChannel reports. The firm owned 181,591 shares of the company’s stock after selling 40,798 shares during the period. Barclays PLC’s holdings in Neurocrine Biosciences were worth $20,922,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at approximately $30,000. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $35,000. Blue Trust Inc. lifted its position in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd boosted its stake in shares of Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after purchasing an additional 130 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Raymond James restated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Barclays decreased their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $165.18.

Neurocrine Biosciences Trading Down 0.1 %

Shares of NASDAQ NBIX opened at $126.70 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market cap of $12.83 billion, a PE ratio of 33.97 and a beta of 0.34. The stock has a 50 day simple moving average of $121.75 and a 200-day simple moving average of $130.62.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.